913368-45-3

Upstream product

• 851728-86-4 ethyl 5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylate 
• 110661-91-1 tert-butyl 4-bromobutyrate 
• 913368-44-2 ethyl 4-(4-tert-butoxy-4-oxobutoxy)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylate 

Downstream Products

• 913368-46-4 2-(2-chlorophenyl)-3-(4-chlorophenyl)-6,7-dihydro-2H-oxepino[3,2-c]pyrazol-8(5H)-one 
• 1370043-41-6 (RS)-2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-methyl-5,6,7,8-tetrahydro-2H-oxepino[3,2-c]pyrazol-8-amine hydrochloride 

Relevant academic research and scientific papers

Design of a potent CB1 receptor antagonist series: Potential scaffold for peripherally-targeted agents

Antagonism of cannabinoid-1 (CB1) receptor signaling has been demonstrated to inhibit feeding behaviors in humans, but CB1-mediated central nervous system (CNS) side effects have halted the marketing and further development of the le

Acylaminobicyclic heteroaromatic compounds and uses thereof

Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.